medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-20-65-69medsovet-2774Research ArticleПрактикаPracticeАктуальность применения мукоактивных препаратов у пациентов с воспалительной патологией лор-органовThe relevance of the application mukoactive preparations in patients with inflammatory pathology of ent organsСвистушкинВ. М.SvistushkinV. M.

д.м.н., профессор, зав. кафедрой болезней уха, горла и носа

НикифороваГ. Н.NikiforovaG. N.

д.м.н., профессор, кафедра болезней уха, горла и носа

ПшонкинаД. М.PshonkinaD. M.

кафедра болезней уха, горла и носа

КарповаО. Ю.KarpovаO. Yu.

д.м.н., профессор, кафедра болезней уха, горла и носа

ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, МоскваРоссияState budgetary educational institution of higher professional education First Moscow state medical University named after I.M. Sechenov of Ministry of healthcare of the Russian Federation,Russian Federation2018141120180206569Copyright © Свистушкин В.М., Никифорова Г.Н., Пшонкина Д.М., Карпова О.Ю., 20182018Свистушкин В.М., Никифорова Г.Н., Пшонкина Д.М., Карпова О.Ю.Svistushkin V.M., Nikiforova G.N., Pshonkina D.M., Karpovа O.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2774

Слизистая оболочка дыхательных путей является первой линией защиты организма человека от различных повреждающих агентов. Эта функция обеспечивается мукоцилиарным клиренсом и его компонентом – мукоцилиарным транспортом. Оптимальная работа реснитчатого эпителия возможна лишь при нормальной реологии слизистого секрета  – вязкости, эластичности, адгезивности. Развитие мукоцилиарной дисфункции является основным патогенетическим механизмом практически всех воспалительных заболеваний дыхательных путей и среднего уха. Основными направлениями лечения пациентов с инфекционно-воспалительными заболеваниями дыхательных путей и уха являются эвакуация патологического секрета, восстановление синтеза физиологической слизи и положительное влияние на реструктуризацию респираторного эпителия. Эффективность мукоактивного препарата определяется его возможностью воздействия сразу на несколько составляющих мукоцилиарного клиренса – регулирование вязкости и состава секрета, процессов его образования и скорости эвакуации. Этим характеристикам соответствует карбоцистеин.

The mucous membrane of the respiratory tract is the first line of protection of the human body from various damaging agents. This function is provided by mucociliary clearance and its component by mucociliary transport. Optimum work of ciliated epithelium is possible only with normal rheology of mucous secretion - viscosity, elasticity, adhesiveness. The development of mucociliary dysfunction is the main pathogenetic mechanism of almost all inflammatory diseases of the respiratory tract and middle ear. The main areas of treatment for patients with infectious and inflammatory diseases of the respiratory tract and ear are evacuation of the pathological secretion, restoration of the synthesis of physiological mucus and a positive effect on the restructuring of the respiratory epithelium. The effectiveness of a mucoactive drug is determined by its ability to directly affect several components of mucociliary clearance - regulation of viscosity and secretion composition, its formation processes and evacuation rate. These characteristics correspond to carbocysteine.

респираторный эпителиймукоцилиарный клиренсмукоактивные препаратыкарбоцистеинrespiratory epitheliummucociliary clearancemucoactive drugscarbocysteineReferencesЧучалин А.Г., Абросимов В.Н. Кашель. М.: ГЭОТАР-Медиа, 2016. 160 с.Chuchalin AG, Abrosimov VN. Cough. M.: GEOTAR-Media. 2016. 160 p.Федосеев Г.Б., Жихарев С.С. Основные механизмы защиты бронхолегочной системы. В кн.: Болезни органов дыхания. Под ред. Н.В. Путова. Т.1. М.: Медицина, 1989: 112-143.Fedoseev GB, Zhikharev SS. The main defense mechanisms of the bronchopulmonary system. In the book: Respiratory system diseases. Under the editorship of Putov NV. V.1. M: Medicine. 1989: 112-143.Мизерницкий Ю.Л., Царегородцев А.Д. Пульмонология детского возраста: проблемы и решения. Выпуск 11. М.: ИД «Медпрактика-М». 2011. 312 с.Mizernitsky YuL, Tsaregorodtsev AD. Pulmonology of childhood: problems and solutions. Issue 11. M.: Medpraktika-M Publishing House. 2011. 312 p.Даниляк И.Г. Кашель: этиология, патофизиология, диагностика, лечение. Пульмонология, 2001, 9(3): 33-37.Danilyak IG. Cough: etiology, pathophysiology, diagnosis, treatment. Pulmonologia, 2001, 9 (3): 33-37.Мизерницкий Ю.Л., Ермакова И.Н. Современные мукоактивные препараты в терапии острых респираторных заболеваний у детей. Consilium Medicum. Педиатрия, 2007, 9(1): 67-71.Mizernitsky YuL, Ermakova IN. Modern mucoactive drugs in the treatment of acute respiratory diseases in children. Consilium Medicum. Pediatria, 2007, 9 (1): 67-71.Рязанцев С.В. Роль мукоактивной терапии в комплексном лечении острых и хронических синуситов. Рос. оториноларингология, 2005, 18: 123-126.Ryazantsev SV. The role of mucoactive therapy in the combination treatment of acute and chronic sinusitis. Ros. Otorinolaringologia, 2005, 18: 123-126Klinika za bolesti uha, nosa, grla i cervkofacijalnu kirurgiju Univerzitetski klinicki centar Tuzla. Med Arh, 1999,53(2): 89-91.Klinika za bolesti uha, nosa, grla i cervkofacijalnu kirurgiju Univerzitetski klinicki centar Tuzla. Med Arh, 1999,53(2): 89-91.Торшин И.Ю., Громова О.А. Экспертный анализ данных в молекулярной фармакологии. М.: МЦНМ. 2012. Т 61. 747 с.Torshin IYu, Gromova OA. Expert data analysis in molecular pharmacology. M.: MCNM, 2012. V 61. 747 p.Primer G. Mucolytic therapy for respiratory system diseases. Clinical-experimental results before and after treatment with Transbronchin. Ther Ggw, 1975 Aug, 114(8): 1251-1266. German. PMID: 1108276.Primer G. Mucolytic therapy for respiratory system diseases. Clinical-experimental results before and after treatment with Transbronchin. Ther Ggw, 1975 Aug, 114(8): 1251-1266. German. PMID: 1108276.Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). [Global Initiative for Chronic Obstruction Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2011)]. Пер. с англ. М.: Российское респираторное общество, 2012. 80 с.Global strategy for the diagnosis, treatment and prevention of chronic obstructive pulmonary disease (Revision in 2011). [Global Initiative for Chronic Obstruction Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2011)]. Trans. from English M.: Russian respiratory society. 2012. 80 p.Jones PW. Quality of life measurements; the value of standartization. Eur Respir Rev, 1997, 7(42): 46-49.Jones PW. Quality of life measurements; the value of standartization. Eur Respir Rev, 1997, 7(42): 46-49.Мещерякова Н.Н., Чикина С.Ю. Муколитическая терапия для больных ХОБЛ. Consilium medicum, 2008, 10(10): 71-76.Meshcheryakova NN, Chikina SYu. Mucolytic therapy in patients with COPD. Consilium medicum, 2008, 10 (10): 71-76.Клячкина И.Л. Еще раз о муколитиках. Consilium medicum, 2008, 10(3): 124-128.Klyachkina IL. Revisiting the mucolytics. Consilium medicum, 2008, 10 (3): 124-128.Самсыгина Г.А. Современные муколитические средства: вопросы выбора терапии. Фарматека, 2005, 2: 7Samsygina GA. Modern mucolytic drugs: issues of choice of therapy. Pharmateca, 2005, 2: 7.Ермакова И.Н., Мизерницкий Ю.Л. Эффективность карбоцистеинового мукорегулятора в терапии острых респираторных инфекций у детей с бронхиальной астмой. Consilium medicum. Педиатрия, 2008, 1(2): 124-127Ermakova IN, Mizernitsky YuL. Effectiveness of carbocysteine (mucoregulator) in the treatment of acute respiratory infections in children with bronchial asthma. Consilium medicum. Pediatria, 2008, 1 (2): 124-127.Magliulo E, Bonizzoni D, Cattaneo E, Scevola D, Concia E. Studies of the clinical effectiveness of the mucolytic drug S-carboxymethylcysteine in the therapy of acute and chronic bronchitis. Minerva Med, 1975 Apr 4, 66(25): 1187-1197. PMID: 1134660.Magliulo E, Bonizzoni D, Cattaneo E, Scevola D, Concia E. Studies of the clinical effectiveness of the mucolytic drug S-carboxymethylcysteine in the therapy of acute and chronic bronchitis. Minerva Med, 1975 Apr 4, 66(25): 1187-1197. PMID: 1134660.Ясуда Х., Ямая M., Сасаки T. Карбоцистеин ингибирует развитие риновирусной инфекции в эпителиальных клетках трахеи человека. Совр. педиатрия, 2010, 3(31): 10-17. (оригинал Eur Respir J, 2006, 28: 51-58.Yasuda H, Yamaya M, Sasaki T. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Sovr. Pediatria, 2010, 3 (31): 10-17. (original Eur Respir J, 2006, 28: 51-58.Cakan G, Turkoz M, Turan T. S-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells. Microb Pathog, 2003, 34(6): 261-265.Cakan G, Turkoz M, Turan T. S-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells. Microb Pathog, 2003, 34(6): 261-265.Braga P, Scaglione F, Scarpazza G, Fraticelli G, Roviaro G, Varoli F, Mariani C, Falchi M, Fraschini F. Comparison between penetration of amoxicillin combined with carbocisteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int J Clin Pharmacol Res, 1985, 5: 331-340.Braga P, Scaglione F, Scarpazza G, Fraticelli G, Roviaro G, Varoli F, Mariani C, Falchi M, Fraschini F. Comparison between penetration of amoxicillin combined with carbocisteine and amoxicillin alone in pathological bronchial secretions and pulmonary tissue. Int J Clin Pharmacol Res, 1985, 5: 331-340.Sun L, Tang L, Xu Y, Wang S. The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke. Respirology, 2010, 15(7): 1064-1071.Sun L, Tang L, Xu Y, Wang S. The effect and mechanism of action of carbocysteine on airway bacterial load in rats chronically exposed to cigarette smoke. Respirology, 2010, 15(7): 1064-1071.Бойкова Н.Э., Тарасова Г.Д. Муколитическая терапия при заболеваниях верхних отделов дыхательного тракта у курящих подростков. Совр. педиатрия, 2011, 2(36): 1-4. /Boykova NE, Tarasova GD. Mucolytic therapy in the upper respiratory tract diseases in smoking adolescents. Sovr. Pediatria, 2011, 2 (36): 1-4.Инструкция по медицинскому применению препарата Бронхобос®, сироп и капсулы. РЛС. 2017. https://www.rlsnet.ru/tn_index_id_24403.htm.Patient Information Leaflet for Bronchobos®, syrup and capsules. RLS. 2017. https://www.rlsnet.ru/tn_index_id_24403.htmZheng CH, Ahmed K. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol, 1999, 43(2): 107-113.Zheng CH, Ahmed K. The effects of S-carboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol, 1999, 43(2): 107-113.Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1998, 157(3 Pt 1): 822-826.Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, Maestrelli P, Ciaccia A, Fabbri LM. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1998, 157(3 Pt 1): 822-826.Hruskovic I, Brezina M, Kayserová H, Langsádl L, Cervenka J. Carbocysteinean effective mucolytic in cystic fibrosis of the lungs. Cesk Pediatr, 1988 Oct, 43(10): 602-604. Slovak. PMID: 3208328.Hruskovic I, Brezina M, Kayserová H, Langsádl L, Cervenka J. Carbocysteinean effective mucolytic in cystic fibrosis of the lungs. Cesk Pediatr, 1988 Oct, 43(10): 602-604. Slovak. PMID: 3208328.Шуганов Е.Г., Салмаси Ж.М., Шуганов А.Е. Клинико-иммунологические эффекты карбоцистеина при лечении больных хронической обструктивной болезнью легких. Альманах клинической медицины, 2014, 35: 66-70.Shuganov EG, Salmasi ZM, Shuganov AE. Clinical and immunological effects of carbocisteine in the treatment of patients with chronic obstructive pulmonary disease. Almanakh Klinicheskoy Meditsiny, 2014, 35: 66-70Yasuda H, Yamaya M, Sasaki T, Inoue D, Nakayama K, Tomita N, Yoshida M, Sasaki H. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc, 2006, 54(2): 378-380.Yasuda H, Yamaya M, Sasaki T, Inoue D, Nakayama K, Tomita N, Yoshida M, Sasaki H. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc, 2006, 54(2): 378-380.Fossati C. Treatment of serous and puruloid bronchial hypersecretions in acute and chronic bronchopneumopathies: our experience with a new mucolytic drug. Clin Ter, 1975 Jul 15, 74(1): 63-82. Review. Italian. PMID: 770054.Fossati C. Treatment of serous and puruloid bronchial hypersecretions in acute and chronic bronchopneumopathies: our experience with a new mucolytic drug. Clin Ter, 1975 Jul 15, 74(1): 63-82. Review. Italian. PMID: 770054.Chezzi GL, Zanocco P, Arrigoni G. Valutazione control-lata di un mucoregolatore, la carbocisteina, in un gruppo di pazzi-enti affetti da rinopatie chroniche catarrali. La Carbocisteina Oggi. Septembre, 1987.Chezzi GL, Zanocco P, Arrigoni G. Valutazione control-lata di un mucoregolatore, la carbocisteina, in un gruppo di pazzi-enti affetti da rinopatie chroniche catarrali. La Carbocisteina Oggi. Septembre, 1987.Spingo G, Teatini GP. Valutazione dell ‘efficacia della carbocisteina nel trattamentodelle otiti catarrali. Oto Rino Laring, 1981, 31: 1-4.Spingo G, Teatini GP. Valutazione dell ‘efficacia della carbocisteina nel trattamentodelle otiti catarrali. Oto Rino Laring, 1981, 31: 1-4.Spingo G, Teatini GP. L ‘impiego di un mucolitico orale nel trattamento dell otiti sieromucose. Nuevo Arch. Ital 0 R L, 1977, 5: 115-122.Spingo G, Teatini GP. L ‘impiego di un mucolitico orale nel trattamento dell otiti sieromucose. Nuevo Arch. Ital 0 R L, 1977, 5: 115-122.Kumasava Т, Ushiro K. Clinical evaluatin of SCMC syrup applied in the treatmeht, lof otitis media with effusion. Acta Otolaringol (Stockh), 1988, (suppl. 458): 56-62.Kumasava Т, Ushiro K. Clinical evaluatin of SCMC syrup applied in the treatmeht, lof otitis media with effusion. Acta Otolaringol (Stockh), 1988, (suppl. 458): 56-62.MC Guinecc RJ. Carboxymethylcysteine in the glue ear syndrome. Brit J Clin Practice, 1977, 31: 7-8, 105-106.MC Guinecc RJ. Carboxymethylcysteine in the glue ear syndrome. Brit J Clin Practice, 1977, 31: 7-8, 105-106.Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004, 59(7): 574-580.Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 2004, 59(7): 574-580.Renou G, Ketari M, Toutée JP, Benzaken J. Medical treatment of seromucous otitis. Rev Laryngol Otol Rhinol (Bord), 1989, 110(3): 327-328. French. PMID: 8638061.Renou G, Ketari M, Toutée JP, Benzaken J. Medical treatment of seromucous otitis. Rev Laryngol Otol Rhinol (Bord), 1989, 110(3): 327-328. French. PMID: 8638061.Steventon GB, Mitchell SC. Efficacy of S-carboxymethyl-L-cysteine for otitis media with effusion. Ear Nose Throat J, 2006 May, 85(5): 296-297. PMID: 16771015.Steventon GB, Mitchell SC. Efficacy of S-carboxymethyl-L-cysteine for otitis media with effusion. Ear Nose Throat J, 2006 May, 85(5): 296-297. PMID: 16771015.Majima Y, Inagaki M, Hirata К et al. Effect of SCMC on nasal mucociliary clearance and viscoelasticity of nasal mucus in chronic sinusitis. Pract Otol (Kyoto), 1987, 808): 1313-1319.Majima Y, Inagaki M, Hirata К et al. Effect of SCMC on nasal mucociliary clearance and viscoelasticity of nasal mucus in chronic sinusitis. Pract Otol (Kyoto), 1987, 808): 1313-1319.Sakakura Y, Majima Y, Saida S et al. Reversibility of reduced mucociliary, in chronic sinusitis. Clin Otolaringol, 1985, 10: 79-83.Sakakura Y, Majima Y, Saida S et al. Reversibility of reduced mucociliary, in chronic sinusitis. Clin Otolaringol, 1985, 10: 79-83.Catalano GB, Mallanino N, Serra A. La carbocisteina nella patologia flogistica cronica rinosinusale. Otorinolaringologia, 1981, 31: 1-11.Catalano GB, Mallanino N, Serra A. La carbocisteina nella patologia flogistica cronica rinosinusale. Otorinolaringologia, 1981, 31: 1-11.Hooper C, Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2008, 3(4): 659-669. PMID: 19281081.Hooper C, Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2008, 3(4): 659-669. PMID: 19281081.Tatsumi K, Fukuchi Y. PEACE Study Group. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc, 2007 Nov, 55(11): 1884-1886. PMID: 17979906.Tatsumi K, Fukuchi Y. PEACE Study Group. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc, 2007 Nov, 55(11): 1884-1886. PMID: 17979906.Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet, 2008, 371(9629): 2013-2018.Zheng JP, Kang J, Huang SG, Chen P, Yao WZ, Yang L, Bai CX, Wang CZ et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet, 2008, 371(9629): 2013-2018.Локшина Э.Э., Зайцева О.В. и др. Опыт применения карбоцистеина у детей с острыми респираторными заболеваниями. РМЖ. Педиатрия, 2012, 91(2): 74-80.Lokshina EE, Zaitseva OV, et al. Experience in using carbocysteine in children with acute respiratory diseases. RMJ. Pediatria, 2012, 91 (2): 74-80Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet, 2008, 371: 2013–2018.Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet, 2008, 371: 2013–2018.Nigam BK, Indian J. S-Carboxymethylcysteine (S-CMC) in bronchography technique. Chest Dis Allied Sci, 1981 Apr-Jun, 23(2): 81-84. PMID: 7298079.Nigam BK, Indian J. S-Carboxymethylcysteine (S-CMC) in bronchography technique. Chest Dis Allied Sci, 1981 Apr-Jun, 23(2): 81-84. PMID: 7298079.Синопальников А.И., Клячкина И.Л. Место муколитических препаратов в комплексной терапии болезней органов дыхания. Российские медицинские вести, 1997, 2(4): 9-18.Sinopalnikov AI, Klyachkina IL. Role of mucolytics in the complex therapy of respiratory diseases. Rossiyskie Medicinskie Vesti, 1997, 2 (4): 9-18.Павлова Т.Г. Бронхобос® (карбоцистеин): возможности клинического применения при заболеваниях околоносовых пазух и среднего уха. http://mfvt.ru/bronxobos-karbocistein.Pavlova TG. Bronchobos® (carbocisteine): options for clinical use in diseases of the paranasal sinuses and middle ear. http://mfvt.ru/ bronxobos-karbocistein.

The authors declare that there are no conflicts of interest present.